FastFacts: Adenovirus vector manufacturing platform using CIMmultus™ QA assures the supply of safe vaccines

Published: Cell & Gene Therapy Insights 2021; 7(8), 1125

Date: October 4, 2021

Presenter: Hana Jug, Project Manager in process development for viral vectors and vaccines

Watch the video or read the poster to learn: 

• Why downstream processing remains one of the main bottlenecks in adenoviral vector manufacturing 
• How an adenoviral vector purification platform using CIMmultus™ QA as the key purification step, secures a fast and robust process with better purity 
• CIMmultus™ QA offers high capacity and high yields of adenovirus, results in cost reduction and overcomes raw material supply bottlenecks